Skip to main content
Premium Trial:

Request an Annual Quote

Exiqon Licenses LNA to Phoenix BioTechnologies

NEW YORK, May 20 - Exiqon has non-exclusively licensed its Locked Nucleic Acids technology to Phoenix BioTechnologies, of Huntsville, Ala.


Under the agreement, Phoenix BioTechnologies will acquires the "recipe" for making LNA, and has the has the rights to manufacture and sell LNA oligonucleotides to the research market. The companies did not disclose the financial terms of the agreement.


LNA is LNA is a proprietary nucleic acid analog, which is incorporated in synthetic DNA oligos to enhance sensitivity in genomics products.


Exiqon, of Copenhagen, has also licensed this technology to DNAPrint of Sarasota, and Eurogentec of Sart-Tilman, Belgium.


The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.